Showing results (41-50 of 108) with videos related to
Sort By:
Pageof 11
BMC Cancer|November 7, 2014
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapyEdwin Choy, James E Butrynski, David C Harmon, et al.Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.Oncogene|March 8, 2018
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53Qi Liu, Liliana Gheorghiu, Michael Drumm, et al.Science (New York, N.Y.)|December 8, 2022
IFITM proteins assist cellular uptake of diverse linked chemotypesKevin Lou, Douglas R Wassarman, Tangpo Yang, et al.Molecular Cancer Therapeutics|July 28, 2021
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing SarcomaDaniel A R Heisey, Sheeba Jacob, Timothy L Lochmann, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2013
Detection of impaired homologous recombination repair in NSCLC cells and tissuesMoritz Birkelbach, Natalie Ferraiolo, Liliana Gheorghiu, et al.Cell Cycle (Georgetown, Tex.)|May 11, 2017
Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212Jessica Wagner, Christina Leah Kline, Marie D Ralff, et al.Molecular Cancer Therapeutics|March 25, 2017
Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer TherapeuticsStuart W Ember, Que T Lambert, Norbert Berndt, et al.Iscience|December 17, 2018
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell LinesVinodh N Rajapakse, Augustin Luna, Mihoko Yamade, et al.Genes & Development|March 1, 2017
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsStephanie A Yazinski, Valentine Comaills, Rémi Buisson, et al.Pageof 11